公开(公告)号：WO2022072671A1

公开(公告)日：2022-04-07

申请号：PCT/US2021/052931

申请日：2021-09-30

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： MURPHY, Andrew J. ,  MACDONALD, Lynn ,  GURER, Cagan ,  MEAGHER, Karolina A. ,  VORONINA, Vera ,  PRASAD, Brinda

IPC: A01K67/027 ,  C07K14/47 ,  C07K14/705 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  A01K67/0275 ,  A01K67/0278 ,  A61K49/0008 ,  C07K14/472 ,  C07K14/70596 ,  C12N15/8509 ,  C12N2015/8527

Abstract: Disclosed herein are genetically modified rodent animals comprising in their genome a nucleic acid which comprises a nucleotide sequence encoding a human CR1 polypeptide, wherein the rodent animals display a human-like expression of the human CR1 polypeptide. Also disclosed herein are isolated rodent cells including rodent embryonic stem cells, and rodent tissues. Further disclosed are nucleic acid vectors and methods for making the genetically modified rodent animals, as well as methods of using such genetically modified rodent animals for screening and testing candidate compounds.

公开(公告)号：WO2019067706A1

公开(公告)日：2019-04-04

申请号：PCT/US2018/053099

申请日：2018-09-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： PRASAD, Brinda ,  TU, Naxin ,  MEAGHER, Karolina ,  MACDONALD, Lynn ,  MURPHY, Andrew ,  STEVENS, Sean

IPC: A01K67/027 ,  C07K14/47

Abstract: Disclosed herein are nucleic acids encoding for and proteins expressing chimeric C1q polypeptides, non-human animals comprising said nucleic acids, and methods of making or using said non-human animals.

公开(公告)号：WO2019067682A1

公开(公告)日：2019-04-04

申请号：PCT/US2018/053064

申请日：2018-09-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： PRASAD, Brinda ,  MURPHY, Andrew ,  MEAGHER, Karolina ,  MASON, Peter

IPC: C07K16/12 ,  C07K16/18 ,  A61K39/00

Abstract: According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a Staphylococcus species target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the Staphylococcus species target antigen with an EC50 of about 10nM or less, and/or are capable of promoting complement deposition on the Staphylococcus species with an EC50 of about 10nM. The antibodies of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of a Staphylococcus species is desired and/or therapeutically beneficial, for example, for treating staphylococcal infections including a skin infection, cellulitis, pneumonia, meningitis, urinary tract infection, toxic shock syndrome, endocarditis, osteomyelitis, bacteremia, or sepsis, or for preventing or treating a staphylococcus infection that occurs as a result of a surgical procedure.

公开(公告)号：WO2020167919A1

公开(公告)日：2020-08-20

申请号：PCT/US2020/017889

申请日：2020-02-12

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： KYRATSOUS, Christos ,  LIN, Chia-Yang ,  MURPHY, Andrew J. ,  PRASAD, Brinda ,  STAHL, Neil

IPC: A61K39/00 ,  A61P31/04 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12 ,  C07K16/18 ,  C07K16/28

Abstract: According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an EC 50 of about 10 nM or less, and/or are capable of promoting complement deposition on the target antigen with an EC 50 of about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and/or therapeutically beneficial.

公开(公告)号：WO2020106814A1

公开(公告)日：2020-05-28

申请号：PCT/US2019/062370

申请日：2019-11-20

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： ZUMSTEG, Anna ,  KYRATSOUS, Christos ,  PRASAD, Brinda ,  COPPI, Alida

IPC: C07K16/12 ,  A61K39/00

Abstract: Speciated antibodies or antigen-binding fragments that bind staphylococcal antigens are provided, where the antibodies and antigen-binding fragments have attenuated Fc binding to Protein A or homologous protein. Compositions comprising the antibodies and methods of use are also provided. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or kidney bacterial titers, and treating symptoms associated with staphylococcal infection. The antibodies may also prevent the severity and/or duration of the primary disease.

公开(公告)号：WO2019067706A4

公开(公告)日：2019-04-04

申请号：PCT/US2018/053099

申请日：2018-09-27

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： PRASAD, Brinda ,  TU, Naxin ,  MEAGHER, Karolina ,  MACDONALD, Lynn ,  MURPHY, Andrew ,  STEVENS, Sean

IPC: A01K67/027 ,  C07K14/47

Abstract: Disclosed herein are nucleic acids encoding for and proteins expressing chimeric C1q polypeptides, non-human animals comprising said nucleic acids, and methods of making or using said non-human animals.